THC testing has become one of the most confusing areas in workplace drug screening.
Traditionally, drug tests have focused on THC, the primary psychoactive compound in marijuana. Standard panels are designed to detect THC metabolites, which indicate marijuana use.
But the landscape has changed.
Today, employers are increasingly hearing about Delta-8, Delta-10, and synthetic cannabinoids like K2 or Spice. These substances are often grouped under “expanded THC” or alternative cannabinoids, and they don’t always behave the same way in standard drug tests.
Here’s where the confusion comes in.
Most standard drug tests are designed to detect traditional THC. Some alternative cannabinoids may not be consistently identified depending on the test used. This can create gaps between what employers think they are screening for and what is actually being detected.
For organizations, the question is no longer just “Do we test for THC?” It’s “What type of THC or cannabinoid exposure are we trying to understand?”
The answer depends on your policy goals, industry expectations, and how your organization defines workplace safety and compliance.
Clarity matters. As cannabinoid products evolve, so should the way testing programs are evaluated.
Fact Friday takeaway:
THC testing is no longer one-dimensional. Understanding the difference between standard and expanded cannabinoid coverage helps align testing with today’s workplace realities.
Using a credible resource for drug screening supplies helps support consistency and reliability across your program.
